Foresite Capital Management IV, LLC
In its 13F for Q2 2025 (holdings as of June 30, 2025, filed August 12, 2025), Foresite Capital Management IV, LLC reported 6 stock positions worth $123.8 million. Its top holding was Pharvaris (PHVS) at 62.7% of the portfolio, followed by Maze Therapeutics (MAZE, 20.9%) and Lyell Immunopharma (LYEL, 5.7%). Compared with Q1 2025, it opened 1 new position and reduced 1. The biggest buy was a new position in Xenon Pharmaceuticals (XENE) and the biggest sale Kura Oncology (KURA, shares −27%).
- Most Recent 13F
- Q2 2026
- Location
- WEST HOLLYWOOD, CA
- CIK
- 0001704132
- Portfolio Value
- $123.8M (Q2 2025)
- SEC Filing
- 0001104659-25-076815 ↗ filed Aug 12, 2025
Holdings Value
Holdings 6 stocks · $123.8M
| PHVS Pharvaris NV | 62.70% | 4,410,581 | $77.6M | No change |
| MAZE Maze Therapeutics Inc. | 20.93% | 2,111,919 | $25.9M | No change |
| LYEL Lyell Immunopharma Inc. | 5.72% | 800,399 | $7.1M | No change |
| XENE Xenon Pharmaceuticals Inc. | 4.05% | 160,000 | $5.0M | New |
| KURA Kura Oncology Inc. | 3.81% | 816,882 | $4.7M | Reduce -26.5% |
| RLAY Relay Therapeutics Inc. | 2.79% | 1,000,000 | $3.5M | No change |
Portfolio Sells Q1 2025 → Q2 2025
| KURA Kura Oncology Inc. | Reduce -26.5% | 3.81% | −2.80 |
Portfolio Buys Q1 2025 → Q2 2025
| XENE Xenon Pharmaceuticals Inc. | New | 4.05% | +4.05 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 6 | $290.2M | PHVS, CYTK, EIKN, RLAY, XENE |
| Q1 2026 | 8 | $237.1M | PHVS, CYTK, EIKN, LYEL, RLAY |
| Q4 2025 | 7 | $229.7M | PHVS, CYTK, LYEL, MAZE, RLAY |
| Q3 2025 | 6 | $182.6M | PHVS, CYTK, MAZE, LYEL, XENE |
| Q2 2025 | 6 | $123.8M | PHVS, MAZE, LYEL, XENE, KURA |
| Q1 2025 | 5 | $111.1M | PHVS, MAZE, LYEL, KURA, RLAY |
| Q4 2024 | 4 | $108.8M | PHVS, KURA, LYEL, RLAY |
| Q3 2024 | 5 | $153.0M | PHVS, KURA, SNDX, LYEL, RLAY |
| Q2 2024 | 4 | $148.8M | PHVS, KURA, SNDX, LYEL |
| Q1 2024 | 5 | $197.9M | PHVS, KURA, KNTE, SNDX, LYEL |